Which CGRP monoclonal antibody is a receptor-targeted therapy?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which CGRP monoclonal antibody is a receptor-targeted therapy?

CGRP-targeted therapies can be antibodies that either bind the CGRP ligand or bind the CGRP receptor itself. Erenumab is a monoclonal antibody that binds the CGRP receptor, blocking CGRP from activating it, so it functions as a receptor-targeted antibody. The other options are not monoclonal antibodies against the receptor; they are small-molecule antagonists known as gepants that block CGRP signaling without being antibodies. Some CGRP-targeted antibodies do bind the ligand rather than the receptor, but in this set only erenumab acts on the receptor with an antibody.

CGRP-targeted therapies can be antibodies that either bind the CGRP ligand or bind the CGRP receptor itself. Erenumab is a monoclonal antibody that binds the CGRP receptor, blocking CGRP from activating it, so it functions as a receptor-targeted antibody. The other options are not monoclonal antibodies against the receptor; they are small-molecule antagonists known as gepants that block CGRP signaling without being antibodies. Some CGRP-targeted antibodies do bind the ligand rather than the receptor, but in this set only erenumab acts on the receptor with an antibody.

More practice questions